News & Media

Alexion Employees Enhance Their Local Communities during Second Annual Global Day of Service

In November 2017, more than 1,300 Alexion employees supported their local communities with volunteer activities as part of the Company’s second annual Global Day of Service. Activities addressed some of the most pressing needs in our neighborhoods, with a focus on health, wellness, and education. Employees in Europe beautified local schools, parks, and homeless shelters; worked with individuals with intellectual disabilities; visited the elderly, and much more. In addition, in celebration of Alexion’s 10-year anniversary of its EMEA headquarters in Switzerland, the Company has made donations to 10 local charities. Read our Global Day of Service press release.

European Commission Approves Soliris for Patients with Refractory gMG

The European Commission has approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union for this ultra-rare subset of MG patients. Read the press release for more information.

Alexion Receives International Investor Award 2016

Alexion is honored to have received a 2016 International Investor Award from the Greater Paris Investment Agency (Paris-Ile de France Capitale Economique) for its significant investment and growth in Paris, France. Alexion first established its presence in France in 2005 and, in 2015, opened a new Research and Development Center in Paris – its first European research hub for rare and severe diseases. Alexion’s R&D Center Paris, which is located at the campus of the Necker Hospital at the Imagine Institute, focuses on discovery research activities in the fields of cell and molecular biology, genomics, and immunogenicity. Read the press release and learn more about Alexion’s R&D Center.

Alexion Announces Additional Investment in Ireland

Alexion has announced an additional €100 million investment in its Athlone operations in Ireland, which will result in the creation of 50 additional jobs. The investment will see the construction of a new biologics manufacturing facility at the site. Read the media statement.

Alexion Inaugurates New EMEA Headquarters in Zurich

On November 19, 2015, Alexion proudly inaugurated the new regional headquarters for Europe, Middle East and Africa in Zurich. We dedicate our office and our work to patients and their families living with rare and devastating diseases. We are committed to delivering life-transforming therapies to patients in need every day. The opening ceremony was attended by representatives from the business communities as well as members of the local life science cluster and political representatives. Read the press release.

European Commission Approves Strensiq® and Kanuma®

The European Commission has approved Kanuma® (sebelipase alfa) for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency (LAL-D), and Strensiq® (asfotase alfa) for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. Both Kanuma and Strensiq are the first therapies approved in the EU for the treatment of these life-threatening, ultra-rare metabolic disorders. Read the Kanuma press release and the Strensiq press release. For more information, please refer to the full Summary of Product Characteristics (SmPC) for Kanuma and for Strensiq.